The following disclosure replaces the last paragraph on page 101 of the Proxy Statement/Prospectus under
the heading Redemption Rights.
If a holder of public shares exercises its redemption rights, then it will be exchanging
its shares of CAH common stock for cash and will no longer own those shares. You will be entitled to receive cash for these shares only if you properly demand redemption no later than the close of the vote on the Merger Proposal by delivering your
stock certificate (either physically or electronically) to CAHs transfer agent prior to the vote at the special meeting, and provided the Merger is consummated.
The following disclosure replaces the paragraph on page 161 of the Proxy Statement/Prospectus under the heading Stockholder Approval of Merger.
Under CAHs amended and restated certificate of incorporation, in connection with any proposed merger, CAH must seek stockholder
approval of an initial merger at a meeting called for such purpose at which public stockholders may seek to redeem their public shares for cash, subject to the limitations described in the prospectus for CAHs initial public offering.
Accordingly, in connection with the Merger, the CAH public stockholders may seek to redeem their public shares for cash in accordance with the procedures set forth in this proxy statement/prospectus.
Additional information
In connection with the
proposed business combination, LumiraDx has filed with the SEC a registration Statement on Form F-4 in connection with the proposed business combination (the Registration Statement)
containing a preliminary proxy statement of CAH and a preliminary prospectus of LumiraDx, which the SEC has declared effective. On September 3, 2021, CAH filed a definitive proxy statement/prospectus relating to the proposed business
combination and mailed that definitive proxy statement/prospectus to its shareholders. This Supplement does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis
of any investment decision or any other decision in respect of the business combination. CAHs shareholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto
and the definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials will contain important information about LumiraDx, CAH and the proposed business combination. The
definitive proxy statement/prospectus and other relevant materials for the proposed business combination has been mailed to shareholders of CAH as of the record date, which is September 1, 2021, for voting on the proposed business combination.
Such shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, at the SECs website at www.sec.gov, or by
directing a request to CA Healthcare Acquisition Corp., 99 Summer Street, Suite 200 Boston, MA 02110.
Participants in Solicitation
CAH and its directors and executive officers may be deemed participants in the solicitation of proxies from CAHs shareholders with respect to the
proposed business combination. A list of the names of those directors and executive officers and a description of their interests in CAH is contained in the Registration Statement. Additional information regarding the interests of such participants
is contained in the proxy statement/prospectus for the proposed business combination.
LumiraDx and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the shareholders of CAH in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the
proposed business combination is contained in the Registration Statement. Additional information regarding the interests of such participants is contained in the proxy statement/prospectus for the proposed business combination.